First CUH patient in national Covid-19 Trial
Cambridge University Hospitals NHS Foundation Trust has today (Friday, 27 March) enrolled its first patient into a national trial aimed at identifying treatments for Covid-19.
The Randomised Evaluation of Covid-19 Therapy (RECOVERY) Trial, led by Oxford researchers, will test several medications that are safely used for other conditions, and have shown promise in other countries.
The opportunity to join this trial will be offered to adults who are hospitalised with Covid-19 at Addenbrooke's, and other participating NHS hospitals across the country, and who do not have health conditions that would interact with the trial drugs.
There are three drugs being tested in the first stages of the trial, including hydroxychloroquine, which is similar to a drug used to treat malaria. However, the trial follows an adaptive design, which means that if further drugs show promise, they can be added to this trial.
The trial results will be regularly reviewed so that any treatments that are found to be effective can be made available to all patients.
For more information visit: CUH News
Published March 27, 2020
Latest from CCTU
Study shows early treatment can prevent long-term complications in Crohn's disease
An Addenbrooke's-led study is the first to provide clear evidence that using more powerful treatments earlier has long-term benefits for people living with…
Targeting the immune system could prevent future heart attacks, Cambridge-led trial suggests
Cambridge researchers have discovered that an existing therapy which boosts protective immune cells in people who have recently had heart attacks reduces…
Cambridge study finds hot flush treatment has anti-breast cancer activity
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast…
